Investigation of Ubrogepant for Migraine Treatment

Overview of Migraine

Migraine is a neurological condition marked by recurrent headaches, typically localized on one side of the head. These headaches can be accompanied by symptoms such as nausea, visual disturbances, and dizziness. Migraine attacks can persist for hours to days, significantly disrupting daily activities. While the exact causes of migraines remain unclear, research indicates that both genetic and environmental factors may contribute to their onset. Furthermore, neurotransmitters, particularly calcitonin gene-related peptide (CGRP), are believed to play a critical role in migraine attacks. CGRP is known for causing vasodilation in the brain and contributing to inflammation.

Recent Clinical Trial Findings

A recent clinical trial published in the *New England Journal of Medicine* evaluated the safety and efficacy of ubrogepant, a CGRP receptor antagonist, for treating migraines. Ubrogepant functions by targeting the CGRP receptor in nerve cells, preventing the binding of the CGRP neurotransmitter. The randomized trial involved 1,672 participants who were assigned to one of three groups: 556 received 50 mg of ubrogepant, 557 received 100 mg, and 559 were given a placebo.

Results of the Study

The trial reported that 19.2% of participants who took 50 mg of ubrogepant experienced relief from migraine pain, while 21.2% of those who took 100 mg reported similar relief. In contrast, 11.8% of participants in the placebo group experienced pain alleviation. Notably, a significant reduction in migraine symptoms was observed in a large percentage of participants just two hours after taking the medication.

Conclusion and Future Research

The findings suggest that ubrogepant is both safe and effective compared to the placebo for the acute treatment of migraines. However, further studies are necessary to assess the long-term safety of ubrogepant and to compare its efficacy with other treatment options.

References

Dodick, D. W., Lipton, R. B., Ailani, J., Lu, K., Finnegan, M., Trugman, J. M., & Szegedi, A. (2019). Ubrogepant for the treatment of migraine. *New England Journal of Medicine*, 381, 2230–2241. doi: 10.1056/nejmoa1813049
Edvinsson L. Role of CGRP in Migraine. *Handb Exp Pharmacol*. 2019;255:121-130. doi:10.1007/164_2018_201
Migraine. (2019, November 1). Retrieved from https://www.mayoclinic.org/diseases-conditions/migraine-headache/symptoms-causes/syc-20360201.